Development of a real-world database for asthma and COPD: The SingHealth-Duke-NUS-GSK COPD and Asthma Real-World Evidence (SDG-CARE) collaboration

Lam, Shao Wei; Fang, Hao Sen Andrew; Koh, Mariko Siyue; Shantakumar, Sumitra; Yeo, See‐Hwee; Matchar, David B; Ong, Marcus Eng Hock; Poon, Ken Mei Ting; Huang, Liming; Harikrishan, Sudha; Miléa, D.; Burke, Des; Webb, Dave; Ragavendran, Narayanan; Tan, Ngiap Chuan; Loo, Chian Min

doi:10.1186/s12911-022-02071-6

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study is expected to contribute significantly to the understanding and treatment of asthma and obesity in pediatric populations in Qatar. In addition, the databases containing the clinical and operational data sources that will be developed as part of this study can be potentially used for health decision-making and future research in asthma and chronic obstructive pulmonary disease [57,58].…”

Section: Expected Results and Outcomesmentioning

confidence: 99%

Sphingolipids in Childhood Asthma and Obesity (SOAP Study): A Protocol of a Cross-Sectional Study

Antonisamy,

Shailesh,

Hani

et al. 2023

Metabolites

View full text Add to dashboard Cite

Asthma and obesity are two of the most common chronic conditions in children and adolescents. There is increasing evidence that sphingolipid metabolism is altered in childhood asthma and is linked to airway hyperreactivity. Dysregulated sphingolipid metabolism is also reported in obesity. However, the functional link between sphingolipid metabolism, asthma, and obesity is not completely understood. This paper describes the protocol of an ongoing study on sphingolipids that aims to examine the pathophysiology of sphingolipids in childhood asthma and obesity. In addition, this study aims to explore the novel biomarkers through a comprehensive multi-omics approach including genomics, genome-wide DNA methylation, RNA-Seq, microRNA (miRNA) profiling, lipidomics, metabolomics, and cytokine profiling. This is a cross-sectional study aiming to recruit 440 children from different groups: children with asthma and normal weight (n = 100), asthma with overweight or obesity (n = 100), overweight or obesity (n = 100), normal weight (n = 70), and siblings of asthmatic children with normal weight, overweight, or obesity (n = 70). These participants will be recruited from the pediatric pulmonology, pediatric endocrinology, and general pediatric outpatient clinics at Sidra Medicine, Doha, Qatar. Information will be obtained from self-reported questionnaires on asthma, quality of life, food frequency (FFQ), and a 3-day food diary that are completed by the children and their parents. Clinical measurements will include anthropometry, blood pressure, biochemistry, bioelectrical impedance, and pulmonary function tests. Blood samples will be obtained for sphingolipid analysis, serine palmitoyltransferase (SPT) assay, whole-genome sequencing (WGS), genome-wide DNA methylation study, RNA-Seq, miRNA profiling, metabolomics, lipidomics, and cytokine analysis. Group comparisons of continuous outcome variables will be carried out by a one-way analysis of variance or the Kruskal–Wallis test using an appropriate pairwise multiple comparison test. The chi-squared test or a Fisher’s exact test will be used to test the associations between categorical variables. Finally, multivariate analysis will be carried out to integrate the clinical data with multi-omics data. This study will help us to understand the role of dysregulated sphingolipid metabolism in obesity and asthma. In addition, the multi-omics data from the study will help to identify novel genetic and epigenetic signatures, inflammatory markers, and mechanistic pathways that link asthma and obesity in children. Furthermore, the integration of clinical and multi-omics data will help us to uncover the potential interactions between these diseases and to offer a new paradigm for the treatment of pediatric obesity-associated asthma.

show abstract

Section: Expected Results and Outcomesmentioning

confidence: 99%

Sphingolipids in Childhood Asthma and Obesity (SOAP Study): A Protocol of a Cross-Sectional Study

Antonisamy,

Shailesh,

Hani

et al. 2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…The database provides dynamic, realworld data for operational insight, use in evidence-based research and to inform national policy. 14 The delivery of critical care in Singapore is world-class and supplemented by national, regional, and internationally impactful research. Stringent standards with continuous quality improvement initiatives ensure the safety and excellence of Intensive Care Unit (ICU) care, including during the COVID-19 pandemic.…”

mentioning

confidence: 99%

Letter from Singapore

Chotirmall,

Abisheganaden,

Chew

et al. 2023

Respirology

Self Cite

View full text Add to dashboard Cite

Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population

Toh,

Ng,

Goel

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Inhaled corticosteroid (ICS) is the mainstay therapy for asthma, but general adherence is low. There is a paucity of real-world inhaler prescribing and adherence data from Asia and at the population level. To address these gaps, we performed a real-world data analysis of inhaler prescribing pattern and adherence in a multi-ethnic Asian asthma cohort and evaluated the association with asthma outcomes. Methods We performed a retrospective analysis of adult asthma patients treated in the primary and specialist care settings between 2015 to 2019. Medication adherence was measured using the medication possession ratio (MPR), and categorised into good adherence (MPR 0.75–1.2), poor adherence (MPR < 0.75) or medication oversupply (MPR > 1.2). All statistical analyses were performed using R Studio. Results 8,023 patients, mean age 57 years, were evaluated between 2015–2019. Most patients were receiving primary care (70.4%) and on GINA step 1–3 therapies (78.2%). ICS-long-acting beta-2 agonist (ICS-LABA) users increased over the years especially in the primary care, from 33–52%. Correspondingly, inpatient admission and ED visit rates decreased over the years. Short-acting beta-2 agonist overdispensing (3 or more canisters per year) remained high (40.7–46.7%). Between 2015 and 2019, the proportion of patients with poor adherence decreased from 12.8–10.5% (for ICS) and from 30.0–26.8% (for ICS-LABA) respectively. Factors associated with poor adherence included minority ethnic groups (OR 0.73–0.93; compared to Chinese), presence of COPD (OR 0.75, 95% CI 0.59–0.96) and GINA step 4 treatment ladder (OR 0.71, 95% CI 0.61–0.85). Factors associated with good adherence were male gender (OR 1.14, 95% CI 1.01–1.28), single site of care (OR 1.22 for primary care and OR 1.76 for specialist care), GINA step 2 treatment ladder (OR 1.28, 95% CI 1.08–1.50). Good adherence was also associated with less frequent inpatient admission (OR 0.91, 95% CI 0.84–0.98), greater SABA overdispensing (OR 1.66, 95% CI 1.47–1.87) and oral corticosteroids use (OR 1.10, 95% CI 1.05–1.14). Conclusions Inhaled corticosteroid (ICS) adherence has improved generally, however, poor adherence was observed for patients receiving asthma care in both primary and specialist care, and those from the minority ethnicities.

show abstract

Development of a real-world database for asthma and COPD: The SingHealth-Duke-NUS-GSK COPD and Asthma Real-World Evidence (SDG-CARE) collaboration

Cited by 5 publications

References 33 publications

Sphingolipids in Childhood Asthma and Obesity (SOAP Study): A Protocol of a Cross-Sectional Study

Sphingolipids in Childhood Asthma and Obesity (SOAP Study): A Protocol of a Cross-Sectional Study

Letter from Singapore

Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population

Contact Info

Product

Resources

About